Biocept Names Darrell Taylor as Senior Vice President, General Counsel and Chief Compliance Officer
10 Fevereiro 2022 - 10:17AM
Business Wire
Biocept (Nasdaq: BIOC), a leading provider of molecular
diagnostic assays, products, and services, has appointed Darrell
Taylor as Senior Vice President, General Counsel and Chief
Compliance Officer. With more than 30 years of healthcare
experience, Taylor will lead essential aspects of legal, compliance
and privacy efforts, and will report to Biocept President and CEO
Michael Nall.
“Darrell’s strong leadership background and his combination of
diagnostics industry experience and legal expertise makes him an
excellent fit for Biocept,” said Nall. “Darrell is a key addition
to our executive team and will support our initiatives and goals,
as we continue to advance our core oncology business and implement
our COVID-19 testing program. We are pleased to welcome Darrell to
the team.”
Taylor brings extensive healthcare and leadership experience,
including over 20 years as a healthcare attorney honing his skills
at the global law firm DLA Piper. He has provided legal, regulatory
and compliance counsel to leading biopharmaceutical companies as
well as numerous biotech start-ups. Most recently, Taylor served as
Chief Compliance Officer for Precision Diagnostics, and its
CLIA-certified and CAP-accredited clinical laboratory. Prior to
embarking on his law career, Taylor built a strong healthcare
foundation serving in leadership positions in clinical laboratory
operations with Lab Corp of America and various hospitals,
developing and implementing regulatory compliance programs.
“I am excited to join the Biocept team and support company
efforts focused on developing innovative diagnostic solutions for
patients with metastatic cancers, while providing vital testing
services during the COVID-19 pandemic,” Taylor said. “I look
forward to working across the organization from a legal and
compliance perspective, as we continue commercializing CNSide™, our
proprietary assay that uses cerebrospinal fluid to identify,
characterize and monitor tumors that have metastasized to the
central nervous system.”
About Biocept
Biocept, Inc., develops and commercializes molecular diagnostic
assays that provide physicians with clinically actionable
information to aid in the diagnosis, treatment and monitoring of
patients with cancer. In addition to its broad portfolio of
blood-based liquid biopsy tests, the company has developed the
CNSide™ cerebrospinal fluid assay, designed to diagnose cancer that
has metastasized to the central nervous system. Biocept also is
leveraging its molecular diagnostic capabilities to offer
nationwide RT-PCR-based COVID-19 testing and services to support
public health efforts during this unprecedented pandemic. For more
information, visit www.biocept.com. Follow Biocept on Facebook,
LinkedIn and Twitter.
Forward-Looking Statements Disclaimer
This release contains forward-looking statements that are based
upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give
no assurance that such expectations and assumptions will prove to
have been correct. Forward-looking statements are generally
identifiable by the use of words like "will," "designed," "look
forward to" and "potential" or comparable terminology. To the
extent that statements in this release are not strictly historical,
including without limitation statements regarding the potential of
CNSide to diagnose cancer that has metastasized to the central
nervous system and the ability of Biocept’s molecular diagnostic
assays to provide physicians with clinically actionable information
for treating and monitoring patients diagnosed with a variety of
cancers, such statements are forward-looking, and are made pursuant
to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. The reader is cautioned not to put undue
reliance on these forward-looking statements, as these statements
are subject to numerous risks and uncertainties, including the risk
that our products and services may not perform as expected. These
and other risks are described in greater detail under the "Risk
Factors" heading of our Quarterly Report on Form 10-Q for the
quarter ended September 30, 2021, filed with the Securities and
Exchange Commission (SEC) on November 15, 2021. The effects of such
risks and uncertainties could cause actual results to differ
materially from the forward-looking statements contained in this
release. We do not plan to update any such forward-looking
statements and expressly disclaim any duty to update the
information contained in this press release except as required by
law. Readers are advised to review our filings with the SEC, which
can be accessed over the Internet at the SEC's website located at
www.sec.gov.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220210005392/en/
Media: Andrea Sampson, Sampson PR Group
asampson@sampsonprgroup.com, 562-304-0301
Investors: Jody Cain, LHA Investor Relations Jcain@lhai.com,
310-691-7100
Biocept (NASDAQ:BIOC)
Gráfico Histórico do Ativo
De Fev 2024 até Mar 2024
Biocept (NASDAQ:BIOC)
Gráfico Histórico do Ativo
De Mar 2023 até Mar 2024